By: Sloane Airey
The memory care industry in 2024 is at a crossroads, balancing innovation with the risk of regression in testing and treatment advancements. With new drugs, AI technology, and a growing aging population, providers are faced with the choice of embracing the future or holding onto the past. Industry leaders recognize the potential in upcoming changes but emphasize the importance of maintaining a focus on quality and improvement.
While new treatments, such as those integrating AI, show promise, experts like Melissa Dillon from Senior Resource Group (SRG) acknowledge that there is still room for growth and development within the industry. The introduction of innovative solutions, like a recent blood test for Alzheimer’s disease, offers hope for early detection and improved care outcomes, but widespread implementation may take time.
Despite the FDA approval of new drugs targeting Alzheimer’s, memory care operators are proceeding cautiously. Silverado’s Kim Butrum highlights concerns about the adoption of these medications due to cost, side effects, and other factors. While recent advancements show potential for early-stage symptom improvement, challenges remain in ensuring patient satisfaction and accessibility to treatments.
Technology plays a significant role in shaping the future of memory care, with AI applications like TSO Life enhancing operational efficiency and resident experiences. While some providers invest in AI-driven tools for patient monitoring, others, like Silverado, approach these innovations with a focus on evaluating their value within existing care models.
As the industry navigates the path towards improvement, memory care directors like Dillon stress the importance of professional development and strategic decision-making to avoid regressing to outdated practices. By investing in the next generation of senior living executives and consulting industry experts, operators can ensure a forward-thinking approach to incorporating new technologies and trends.
